sitravatinib
Small moleculeexperimental
Sitravatinib (MGCD516) is an experimental drug for the treatment of cancer. It is a small molecule inhibitor of multiple tyrosine kinases. — Wikipedia
Clinical trial activity
39 trials · 20 clinical orgs · 0 marketing orgs
Phase 1
14
Phase 2
27
Phase 3
6
Phase 4
0
Earliest trial started Aug 1, 2014 (NCT02219711)
Timeline
Indications
Studied for
- Biliary Tract Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Squamous Cell · Early Phase 1
- Carcinoma, Transitional Cell · Phase 2
- Drugs, Investigational · Phase 2
- Endometrial Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Esophageal Squamous Cell Carcinoma · Phase 2
- Healthy Volunteers · Phase 1
- Kidney Neoplasms · Phase 1/Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Liposarcoma · Phase 2
- Liver Diseases · Phase 1
- Lung Diseases · Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma · Phase 3
- Melanoma · Phase 2
- Mutation · Phase 2
- Nasopharyngeal Carcinoma · Phase 1
- Neoplasms · Phase 2/Phase 3
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Stomach Neoplasms · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
MERTK inhibitor
- Tyrosine-protein kinase receptor UFOINHIBITOR
AXL inhibitor
- Stem cell growth factor receptorINHIBITOR
KIT inhibitor
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)cc4F)c3s2)nc1.O=C(O)CC(O)C(=O)O- Mol. weight
- 763.78 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSitravatinib ↗
- ChEMBLCHEMBL4298164 ↗
Also known as
- mgcd516
- mgcd516
- mgcd516
- sitravatinib
- sitravatinib
- sitravatinib
- sitravatinib tislelizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06029127 | Phase 2 | Oct 23, 2023 | BeOne Medicines |
| NCT05614453 | Phase 2 | Dec 1, 2022 | Australia New Zealand Gynaecological Oncology Group, BeOne Medicines |
| NCT05564338 | Phase 3 | Dec 1, 2022 | BeOne Medicines |
| NCT05461794 | Phase 2 | Oct 3, 2022 | BeOne Medicines |
| NCT05542342 | Phase 2 | Sep 23, 2022 | BeOne Medicines, Grupo Español Multidisciplinar de Melanoma, Mirati Therapeutics Inc. |
| NCT05419817 | Phase 2 | Sep 8, 2022 | Mirati Therapeutics Inc., University of Pittsburgh |
| NCT05407519 | Phase 2 | Jul 25, 2022 | Anhui Medical University, Chinese Academy of Medical Sciences, Hacettepe University, Jiao Tong University |
| NCT05228496 | Phase 2 | Mar 17, 2022 | Chinese Academy of Medical Sciences |
| NCT05255276 | Phase 1 | Jan 29, 2022 | Mirati Therapeutics Inc. |
| NCT04925986 | Phase 2 | Jan 1, 2022 | Mirati Therapeutics Inc., Yale University |
| NCT05104801 | Phase 2 | Nov 30, 2021 | Chinese Academy of Medical Sciences |
| NCT04921358 | Phase 3 | Jul 27, 2021 | BeOne Medicines |
| NCT04935112 | Phase 1 | Jul 7, 2021 | Mirati Therapeutics Inc. |
| NCT04904302 | Phase 2 | Jul 1, 2021 | University of Texas at Houston |
| NCT04887870 | Phase 2/Phase 3 (Phase 3) | Jun 30, 2021 | Mirati Therapeutics Inc. |
| NCT04887194 | Phase 1 | Mar 26, 2021 | Mirati Therapeutics Inc. |
| NCT04800614 | Phase 1 | Mar 15, 2021 | Mirati Therapeutics Inc. |
| NCT04772612 | Phase 1 | Mar 12, 2021 | Mirati Therapeutics Inc. |
| NCT04734262 | Phase 2 | Jan 30, 2021 | Fudan University |
| NCT05176925 | Phase 2 | Jan 10, 2021 | Fudan University |
Showing 20 of 39 trials
Page 1 / 2
Organizations
Research & Development (20)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mirati Therapeutics Inc. | For profit | 19 | 12 | 3 | 2014 |
| BeOne Medicines | For profit | 14 | 10 | 3 | 2018 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 3 | 2 | 1 | 2021 |
| Fudan University | Academic/Hospital | 2 | 2 | 1 | 2021 |
| University of Texas at Houston | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Anhui Medical University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Australia New Zealand Gynaecological Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2019 |
| Celgene | For profit | 1 | 1 | 1 | 2019 |
| Columbia University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| German CLL Study Group | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Grupo Español Multidisciplinar de Melanoma | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Hacettepe University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Seoul National University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Cologne | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2022 |
20 organizations
Page 1 / 1